UCB

UCB is a global biopharma focused on severe diseases with operations in about 40 countries and global revenue of € 3.2 billion in 2011. UCB combine biology and chemistry to make major breakthroughs. By integrating their expertise in large, antibody-based molecules and small, chemically-derived molecules, UCB can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.